• SENSEX
    NIFTY 50
Business

Cipla remains confident after US FDA observations, says de-risking plan in place 

Updated : October 11, 2019 03:58 PM IST

According to the company, the observations mainly centered on facilities, equipment and infrastructure. 
The share price fell up to 7.74 percent to touch its five-year low of Rs 389.6 on the NSE after the US regulator issued 12 observations to the plant.
Cipla remains confident after US FDA observations, says de-risking plan in place 

You May Also Like

Live TV

recommended for you

Advertisement